AstraZeneca (LSE:AZN) recently reported robust earnings results, with significant year-over-year increases in sales, revenue, ...

AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca CEO Pascal Soriot said it’s time for the U.S. to start paying more reasonable prices for new drugs, which are closer to what other wealthy countries pay, in a rare stance in an industry ...

AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Cambridge: AstraZeneca has announced that the company's supplemental Biologics License Application (sBLA) for Imfinzi ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

Imfinzi plus chemo cut progression or death risk in early gastric cancer; the FDA's decision is expected late 2025 following breakthrough designation.

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...

AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...